Exploring the complex role of gut microbiome in the development of precision medicine strategies for targeting microbial imbalance-induced colon cancer

• Published in: Folia microbiologica Vol. 68; no. 5; pp. 691 - 701
• Main Authors: Pal, Pamela, Shastry, Rajesh P.
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.10.2023; Springer Nature B.V
• Subjects: Antibiotics; Applied Microbiology; Biomedical and Life Sciences; Colon cancer; Colorectal cancer; Customization; Digestive system; Dysbacteriosis; Environmental Engineering/Biotechnology; Fecal microflora; Health services; Immunology; Intestinal microflora; Life Sciences; Metagenomics; Microbiology; Microbiomes; Microbiota; Microorganisms; Patients; Peptides; Precision medicine; Probiotics; Quorum sensing; Review; Side effects; Transplantation; Colon cancer; Quorum sensing peptides; Precision medicine; Dysbiosis; Immunotherapy; Microbiome
• ISSN: 0015-5632; 1874-9356
• DOI: 10.1007/s12223-023-01085-5

The gut microbiome has been increasingly recognized as a key player in the development and progression of colon cancer. Alterations in the gut microbiota, known as dysbiosis, can lead to a variety of medical issues. Microbial adaptation through signals and small molecules can enhance pathogen colonization and modulate host immunity, significantly impacting disease progression. Quorum sensing peptides and molecules have been linked to the progression of colon cancer. Various interventions, such as fecal microbiota transplantation, probiotics, prebiotics, synbiotics, and antibiotics, have been used to reverse dysbiosis with mixed results and potential side effects. Thus, a personalized approach to treatment selection based on patient characteristics, such as individual gut microbiota manipulation, is necessary to prevent and treat diseases like colon cancer. With advances in metagenomic sequencing and other omics technologies, there has been a growing interest in developing precision medicine strategies for microbial imbalance-induced colon cancer. This review serves as a comprehensive synthesis of current knowledge on the gut microbiome involvement in colon cancer. By exploring the potential of utilizing the gut microbiome as a target for precision medicine, this review underscores the exciting opportunities that lie ahead. Although challenges exist, the integration of microbiome data into precision medicine approaches has the potential to revolutionize the management of colon cancer, providing patients with more personalized and effective treatment options.